NCT07890090 THE EFFECT OF EDUCATION IN PATIENTS WITH HYPERTENSION
| NCT ID | NCT07890090 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Inonu University |
| Condition | Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 76 participants |
| Start Date | 2026-10-01 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 76 participants in total. It began in 2026-10-01 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Educational interventions play an extensive role in the literature on hypertension disease management. It has been reported that patient education practices increase individuals' level of knowledge, improve sleep and quality of life, ensure the control of hypertension, are effective in developing self-management skills, reduce body weight and body mass index, are effective in controlling harmful lifestyle habits, increase treatment adherence and healthy lifestyle behaviors, improve health literacy and self-efficacy levels, positively affect rational medication use, and strengthen adaptation to the disease. Accordingly, educational interventions for patients with hypertension play a fundamental role in improving treatment success and long-term health outcomes by supporting individuals' active participation in disease management. However, most studies conducted in the context of hypertension have focused on medication adherence, blood pressure control, or the physiological effects of lifestyle changes. In contrast, no study examining the effects of educational interventions for disease management on the health perception and burnout levels of individuals with hypertension has been found in the literature. The aim of this study is to determine the effects of disease management education provided to individuals diagnosed with hypertension on their health perception and burnout levels. The study aims to provide practical implications for both individual patient outcomes (psychosocial variables) and healthcare practices (the planning and implementation of patient education programs).
Eligibility Criteria
\*\*Inclusion Criteria\*\* * Individuals who agree to participate in the study. * Individuals aged 18 years or older. * Individuals diagnosed with hypertension for at least 6 months. * Individuals who are literate. * Individuals who have sufficient proficiency in Turkish to communicate effectively and speak Turkish. * Individuals whose physical and cognitive health status is adequate to complete the data collection forms planned for the study (i.e., individuals without psychiatric, hearing, or visual impairments). * Individuals who have not previously received structured education on hypertension management. * Outpatients and inpatients admitted to Batman Training and Research Hospital. \*\*Exclusion Criteria\*\* * Individuals with significant intellectual, psychological, or cognitive impairments * Individuals with disabilities resulting from physical functional limitations
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07890090 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07890090 currently recruiting?
Yes, NCT07890090 is actively recruiting participants. Contact the research team at medet.korkmaz@inonu.edu.tr for enrollment information.
Where is the NCT07890090 trial being conducted?
This trial is being conducted at Batman, Turkey (Türkiye).
Who is sponsoring the NCT07890090 clinical trial?
NCT07890090 is sponsored by Inonu University. The trial plans to enroll 76 participants.